← Leaderboards
Noriyuki Kasahara
University Of Southern California
$14,684,256
Attributed
$14,684,256
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$14,684,256 · 14
By mechanism
R01$8,108,783 · 5
U01$2,879,389 · 1
P30$1,762,998 · 3
R21$798,289 · 1
P01$568,091 · 2
R33$403,748 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Laurence H Kedes$5,584,649
- David T Woodley$8,753,993
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVectorGenesCellsResearch PersonnelGene TransferVirusIn VivoProgramsMediatingNeoplastic CellTransgenesProductionDesign And ConstructionGliomaRetroviridaeBaseFlucytosineSafetySuicide GeneDesignNormal Tissue MorphologyClinical TrialsProdrugs
Grant awards (52)
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer$519,704
R01 · FY2022 · CA · contact PI
GALV-Based Retroviral Replicating Vectors for Glioma Gene Therapy$403,748
R33 · FY2021 · NS · contact PI
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer$530,309
R01 · FY2020 · CA · contact PI
GALV-Based Retroviral Replicating Vectors for Glioma Gene Therapy$396,833
R21 · FY2020 · NS · contact PI
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer$511,480
R01 · FY2019 · CA · contact PI
GALV-Based Retroviral Replicating Vectors for Glioma Gene Therapy$401,456
R21 · FY2019 · NS · contact PI
Core D: Integrated Molecular Technologies$142,117
P30 · FY2019 · DK · contact PI
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer$504,040
R01 · FY2018 · CA · contact PI
Core D: Integrated Molecular Technologies$146,969
P30 · FY2018 · DK · contact PI
Vector and Human Acinar Core$112,318
P01 · FY2018 · DK · contact PI
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer$504,040
R01 · FY2017 · CA · contact PI
Core D: Integrated Molecular Technologies$143,990
P30 · FY2017 · DK · contact PI
Vector and Human Acinar Core$112,318
P01 · FY2017 · DK · contact PI
Core D: Integrated Molecular Technologies$143,990
P30 · FY2016 · DK · contact PI
Vector and Human Acinar Core$112,318
P01 · FY2016 · DK · contact PI
Core D: Integrated Molecular Technologies$143,990
P30 · FY2015 · DK · contact PI
Vector and Human Acinar Core$112,318
P01 · FY2015 · DK · contact PI
Vector and Human Acinar Core$118,819
P01 · FY2014 · DK · contact PI
Vector Shared Resource$153,322
P30 · FY2013 · CA · contact PI
Translational Development of Replication-Competent Retrovirus Vectors$1
U01 · FY2013 · NS · contact PI
Translational Development of Replication-Competent Retrovirus Vectors$939,203
U01 · FY2012 · NS · contact PI
Vector Shared Resource$123,847
P30 · FY2012 · CA · contact PI
Translational Development of Replication-Competent Retrovirus Vectors$913,956
U01 · FY2011 · NS · contact PI
Cellular Transduction with Replication-Competent Retrovirus Vectors$476,828
R01 · FY2011 · CA · contact PI
Vector Shared Resource$98,565
P30 · FY2011 · CA · contact PI
Translational Development of Replication-Competent Retrovirus Vectors$1,026,229
U01 · FY2010 · NS · contact PI
Cellular Transduction with Replication-Competent Retrovirus Vectors$434,515
R01 · FY2010 · CA · contact PI
Vector Shared Resource$122,327
P30 · FY2010 · CA · contact PI
Cellular Transduction with Replication-Competent Retrovirus Vectors$481,936
R01 · FY2009 · CA · contact PI
CORE--MOLECULAR BIOLOGY AND VECTORS$126,400
P30 · FY2009 · DK · contact PI
Vector Shared Resource$115,875
P30 · FY2009 · CA · contact PI
Cellular Transduction with Replication-Competent Retrovirus Vectors$467,899
R01 · FY2008 · CA · contact PI
Combining Virotherapy and Immunotherapy for Cancer$300,313
R01 · FY2008 · CA · contact PI
CORE--MOLECULAR BIOLOGY AND VECTORS$126,400
P30 · FY2008 · DK · contact PI
Cellular Transduction with Replication-Competent Retrovirus Vectors$480,116
R01 · FY2007 · CA · contact PI
Combining Virotherapy and Immunotherapy for Cancer$300,313
R01 · FY2007 · CA · contact PI
CORE--MOLECULAR BIOLOGY AND VECTORS$57,260
P30 · FY2007 · DK · contact PI
Combining Virotherapy and Immunotherapy for Cancer$309,282
R01 · FY2006 · CA · contact PI
CORE--MOLECULAR BIOLOGY AND VECTORS$58,973
P30 · FY2006 · DK · contact PI
Combining Virotherapy and Immunotherapy for Cancer$315,871
R01 · FY2005 · CA
Cellular Trans. by Retrotransposon-Adenovirus Hybrid Ve.$305,095
R01 · FY2005 · CA
CORE--MOLECULAR BIOLOGY AND VECTORS$58,973
P30 · FY2005 · DK
Combining Virotherapy and Immunotherapy for Cancer$313,821
R01 · FY2004 · CA
Cellular Trans. by Retrotransposon-Adenovirus Hybrid Ve.$311,605
R01 · FY2004 · CA
Cellular Trans. by Retrotransposon-Adenovirus Hybrid Ve.$309,575
R01 · FY2003 · CA
Cellular Trans. by Retrotransposon-Adenovirus Hybrid Ve.$329,875
R01 · FY2002 · CA
TARGETING OF RETROVIRAL REPLICATION TO TUMORS$0
P01 · FY2002 · CA
TRANSCRIPTIONAL TARGETING OF RETROVIRAL REPLICATION$184,298
R01 · FY2001 · CA
ANTI-ANGIOGENIC GENE THERAPY FOR RHEUMATOID ARTHRITIS$81,250
R03 · FY2001 · AR
TARGETING OF RETROVIRAL REPLICATION TO TUMORS$0
P01 · FY2001 · CA
TRANSCRIPTIONAL TARGETING OF RETROVIRAL REPLICATION$217,868
R01 · FY2000 · CA
ANTI-ANGIOGENIC GENE THERAPY FOR RHEUMATOID ARTHRITIS$81,708
R03 · FY2000 · AR